Expert opinion on investigational drugsHumansAnimalsGlucagon-Like Peptide-1 Receptor AgonistsMultiple SclerosisNeuroprotective Agents
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions.
Afsaneh Shirani, Olaf Stuve
Published: 202510.1080/13543784.2025.2587277
Abstract
INTRODUCTION: This review evaluates the potential of glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs) - first developed for type 2 diabetes and later approved for chronic weight management and additional indications - to be repurposed as neuropro…
Preview only. Read the full abstract at the source